Laurent Pharmaceuticals Welcomes New Investors and Announces Scientific Breakthrough with LAU-7b in Cystic Fibrosis

25 October 2018

Laurent Pharmaceuticals Inc., a biopharmaceutical company developing LAU-7b (oral fenretinide) first-in-class pro-resolving drug for Cystic Fibrosis (CF), today announced new financing...

Read More

Laurent Pharmaceuticals reaches agreement with US Cystic Fibrosis Foundation to increase Development Award to $US 5M

14 March 2018

Laurent Pharmaceuticals Inc. (the “Company”), today announced that it has reached an agreement to receive an additional US$ 2 million commitment...

Read More


Laurent Pharma to participate to H.C. Wainwright 23rd Annual Global Investment Conference, September 13-15, 2021